Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review
Pediatrics International · 2024
DOI: 10.1111/ped.15822 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatrics International, 2024. Verfasst von Hiroki Kitaoka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Furosemide, Cyclooxygenase Inhibitors, Infant, Premature. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Although furosemide is used during cyclooxygenase (COX) inhibitor therapy for patent ductus arteriosus (PDA), there are concerns regarding increased ductal closure failure and acute renal failure (ARF). This systematic review explores the effects of furosemide during COX inhibitor therapy.
Methods
We searched MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi databases for randomized clinical trials that assessed furosemide during COX inhibitor therapy for PDA in preterm infants. The primary outcome measure was PDA closure failure. Mortality and other complications were also assessed. The risk of bias was assessed using the Cochrane risk‐of‐bias tool for randomized control trials, and the certainty of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation criteria.
Results
Overall, three trials involving 121 patients were included in the analysis. The overall incidence of PDA closure failure was 28%. Although the result of PDA closure failure, mortality, and ARF were obtained, other outcomes were not described in any of the studies. The risk of bias was high. The risk of PDA closure failure did not increase with furosemide administration. Furosemide was not associated with decreased mortality but was associated with an increased risk of ARF (risk ratio, 4.96 [95% confidence interval: 1.80–13.6]). The certainty of evidence for all outcomes was very low.
Conclusion
Although furosemide is not associated with an increased risk of PDA closure failure or mortality, the risk of ARF increases after furosemide administration during COX inhibitor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Neonatology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan.
- Division of Neonatology, Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Izumi, Japan.
- Department of Pediatrics, Saitama Medical Center Saitama Medical University, Kawagoe, Japan.
ORCID-Profile: Hiroki Kitaoka, Masatoshi Nozaki, Satoshi Masutani, Tetsuya Isayama, Katsuaki Toyoshima
Zitieren
APA
Kitaoka, H., Terada, Y., Tanaka, K., Nozaki, M., Masutani, S., Isayama, T., & Toyoshima, K. (2024). Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review. Pediatrics International. https://doi.org/10.1111/ped.15822
Vancouver
Kitaoka H, Terada Y, Tanaka K, Nozaki M, Masutani S, Isayama T, et al. Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review. Pediatrics International. 2024. doi:10.1111/ped.15822
BibTeX
@article{Kitaoka2024,
author = {Kitaoka, Hiroki and Terada, Yusuke and Tanaka, Kosuke and Nozaki, Masatoshi and Masutani, Satoshi and Isayama, Tetsuya and Toyoshima, Katsuaki},
title = {Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review},
journal = {Pediatrics International},
year = {2024},
doi = {10.1111/ped.15822}
}
EUVIMED